Abstract #4104
Prostate Cancer localization with a Multiparametric MR Approach (PCaMAP): separating PCa from benign tissue in a multi-center study
Marnix C. Maas 1 , Alan J. Wright 1 , Kirsten M. Selns 2,3 , Masoom A. Haider 4 , Katarzyna J. Macura 5 , Daniel J.A. Margolis 6 , Berthold Kiefer 7 , Jurgen J. Ftterer 1 , and Tom W.J. Scheenen 1
1
Radiology, Radboud University Medical
Center, Nijmegen, Netherlands,
2
Department
of Circulation and Medical Imaging, Norwegian University
of Science and Technology, Trondheim, Norway,
3
St.
Olavs Hospital, Trondheim University Hospital,
Trondheim, Norway,
4
Sunnybrook
Health Sciences Centre, University of Toronto, Toronto,
Ontario, Canada,
5
Russell
H. Morgan Department of Radiology and Radiological
Science, Johns Hopkins University, Baltimore, MD, United
States,
6
UCLA
David Geffen School of Medicine, Los Angeles, CA, United
States,
7
Siemens
AG Healthcare Sector, Erlangen, Germany
We present initial results of a multi-center trial aimed
at assessing the diagnostic accuracy of 3T
multi-parametric MR imaging and spectroscopy in
distinguishing clinically significant prostate cancer
(PCa) from other prostatic tissue, with whole-mount
section histopathology as the gold standard. Good
separation between PCa and benign tissues was found for
multi-center ADC data; DCE and MRSI need further
analysis before solid conclusions about these methods
performance can be drawn. The validation part of this
prospective trial will be used to determine the
parameters contributing most to the detection and
localization of clinically significant PCa as well as
their optimal thresholds.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
